Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.50 | 91.30 | -1.01% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,960.64 | 134.98 | 0.54% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,950.36 | 69.96 | 0.54% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,664.50 | 92.70 | -1.06% |
| SSE Composite Index | 3,548.35 | 13.87 | 0.39% |